Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 8; no. 5; pp. e41 - e42
Main Authors Rudin, Charles M., Hong, Kelvin, Streit, Michael
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2013
International Association for the Study of Lung Cancer
Subjects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Drug Resistance, Neoplasm - genetics
Female
Humans
Imidazoles - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
MAP Kinase Signaling System - genetics
Middle Aged
Mutation
Oximes - therapeutic use
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins p21(ras)
ras Proteins - genetics
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Case Study-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-2
ISSN:1556-0864
1556-1380
DOI:10.1097/JTO.0b013e31828bb1b3